<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240912061131&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240912061131&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 12 Sep 2024 10:11:32 +0000</lastbuilddate>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Atheroimmunology: keeping the immune system in atherosclerosis in check</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39261586/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 11. doi: 10.1038/s41569-024-01075-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39261586/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39261586</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01075-1>10.1038/s41569-024-01075-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39261586</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Claudia Monaco</dc:creator>
<dc:creator>Lea Dib</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Atheroimmunology: keeping the immune system in atherosclerosis in check</dc:title>
<dc:identifier>pmid:39261586</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01075-1</dc:identifier>
</item>
<item>
<title>Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1107-1118. doi: 10.1016/j.jacc.2024.06.038.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized dosing or a change in drug selection. Most evidence supports guiding therapy based on the CYP2C19 allelic variants in patients with an indication for dual antiplatelet therapy. In ticagrelor-treated or prasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, whereas in patients treated with clopidogrel, an escalation strategy may prevent ischemic events. Although the clinical results are promising, few hospitals have implemented these strategies. New results, technological advancements, and growing experience may potentially overcome current barriers for implementation in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260933</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.038>10.1016/j.jacc.2024.06.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260933</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wout W A van den Broek</dc:creator>
<dc:creator>Brenden S Ingraham</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>Craig R Lee</dc:creator>
<dc:creator>Larisa H Cavallari</dc:creator>
<dc:creator>Jesse J Swen</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:39260933</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.038</dc:identifier>
</item>
<item>
<title>Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1104-1106. doi: 10.1016/j.jacc.2024.06.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260932</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.042>10.1016/j.jacc.2024.06.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260932</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Harrison W Farber</dc:creator>
<dc:creator>Noah C Schoenberg</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:39260932</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.042</dc:identifier>
</item>
<item>
<title>Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Plasma IgG fucosylation informs PAH prognosis independent of established factors, offering additional value for predicting PAH outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1092-1103. doi: 10.1016/j.jacc.2024.05.077.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide is the only blood biomarker in established risk calculators for pulmonary arterial hypertension (PAH). Profiling systemic-originated plasma immunoglobulin G (IgG) N-glycans, which reflect different components of the pathophysiology of PAH including immune dysregulation and inflammation, may improve PAH risk assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to identify plasma IgG N-glycan biomarkers that predict survival in PAH to improve risk assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cohort study examined 622 PAH patients from 2 national centers (Beijing [discovery] cohort: n = 273; Shanghai [validation] cohort: n = 349). Plasma IgG N-glycomes were profiled by a robust mass spectrometry-based method. Prognostic IgG N-glycan traits were identified and validated in the 2 cohorts using Cox regression and Kaplan-Meier survival analyses. The added value of IgG N-glycan traits to previously established risk models was assessed using Harrell C-indexes and survival analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Plasma IgG fucosylation was found to predict survival independent of age and sex in the discovery cohort (HR: 0.377; 95% CI: 0.168-0.845; P = 0.018) with confirmation in the validation cohort (HR: 0.445; 95% CI: 0.264-0.751; P = 0.005). IgG fucosylation remained a robust predictor of mortality in combined cohorts after full adjustment and in subgroup analyses. Integrating IgG fucosylation into previously established risk models improved their predictive capacity, marked by an overall elevation in Harrell C-indexes. IgG fucosylation was useful in further stratifying the intermediate-risk patients classified by a previously established model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Plasma IgG fucosylation informs PAH prognosis independent of established factors, offering additional value for predicting PAH outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260931</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.077>10.1016/j.jacc.2024.05.077</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260931</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ze-Jian Zhang</dc:creator>
<dc:creator>Chao Liu</dc:creator>
<dc:creator>Jie-Ling Ma</dc:creator>
<dc:creator>Jing-Si Ma</dc:creator>
<dc:creator>Jia Wang</dc:creator>
<dc:creator>Ruo-Nan Li</dc:creator>
<dc:creator>Dan Lu</dc:creator>
<dc:creator>Yu-Ping Zhou</dc:creator>
<dc:creator>Tian-Yu Lian</dc:creator>
<dc:creator>Si-Jin Zhang</dc:creator>
<dc:creator>Jing-Hui Li</dc:creator>
<dc:creator>Lan Wang</dc:creator>
<dc:creator>Kai Sun</dc:creator>
<dc:creator>Chun-Yan Cheng</dc:creator>
<dc:creator>Wen-Hui Wu</dc:creator>
<dc:creator>Xin Jiang</dc:creator>
<dc:creator>Zhi-Cheng Jing</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:39260931</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.077</dc:identifier>
</item>
<item>
<title>Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1089-1091. doi: 10.1016/j.jacc.2024.07.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260930</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.019>10.1016/j.jacc.2024.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260930</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle</dc:title>
<dc:identifier>pmid:39260930</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.019</dc:identifier>
</item>
<item>
<title>Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1078-1088. doi: 10.1016/j.jacc.2024.06.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the effects of SGLT1 and SGLT2 inhibition on health status are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: These prespecified analyses of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial examined the effects of sotagliflozin vs placebo on HF-related health status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: SOLOIST-WHF randomized patients hospitalized or recently discharged after a worsening HF episode to receive sotagliflozin or placebo. The primary endpoint was total number of HF hospitalizations, urgent HF visits, and cardiovascular death. Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score was a prespecified secondary endpoint. This analysis evaluated change in the KCCQ-12 score from baseline to month 4.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,222 patients randomized, 1,113 (91%) had complete KCCQ-12 data at baseline and 4 months. The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups. Sotagliflozin vs placebo reduced the risk of the primary endpoint consistently across KCCQ-12 tertiles (P<sub>trend</sub> = 0.54). Sotagliflozin-treated patients vs those receiving placebo experienced modest improvement in KCCQ-12 at 4 months (adjusted mean change: 4.1 points; 95% CI: 1.3-7.0 points; P = 0.005). KCCQ-12 improvements were consistent across prespecified subgroups, including left ventricular ejection fraction &lt;50% or ≥50%. More patients receiving sotagliflozin vs those receiving placebo had at least small (≥5 points) improvements in KCCQ-12 at 4 months (OR: 1.38; 95% CI: 1.06-1.80; P = 0.017).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260929</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.036>10.1016/j.jacc.2024.06.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260929</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>Julia B Lewis</dc:creator>
<dc:creator>Matthew C Riddle</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Jeffrey M Testani</dc:creator>
<dc:creator>Christopher S Wilcox</dc:creator>
<dc:creator>Michael Davies</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF</dc:title>
<dc:identifier>pmid:39260929</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.036</dc:identifier>
</item>
<item>
<title>Medical Therapy for Aortic Stenosis: Abandon Ship or Full Steam Ahead?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1076-1077. doi: 10.1016/j.jacc.2024.07.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260928</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.011>10.1016/j.jacc.2024.07.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260928</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Neil J Craig</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Medical Therapy for Aortic Stenosis: Abandon Ship or Full Steam Ahead?</dc:title>
<dc:identifier>pmid:39260928</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.011</dc:identifier>
</item>
<item>
<title>Effect of Evogliptin on the Progression of Aortic Valvular Calcification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This exploratory study did not demonstrate the protective effect of evogliptin on AV calcification. Favorable ^(18)F-NaF PET results and possible suppression of aortic valve calcification with longer medication use in the evogliptin groups suggest the need for larger confirmatory trials. (A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1064-1075. doi: 10.1016/j.jacc.2024.06.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Medical therapy for aortic stenosis (AS) remains an elusive goal.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to establish whether evogliptin, a dipeptidyl peptidase-4 inhibitor, could reduce AS progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 228 patients (age 67 ± 11 years; 33% women) with AS were randomly assigned to receive placebo (n = 75), evogliptin 5 mg (n = 77), or evogliptin 10 mg (n = 76). The primary endpoint was the 96-week change in aortic valve calcium volume (AVCV) on computed tomography. Secondary endpoints included the 48-week change in active calcification volume measured using <sup>18</sup>F-sodium fluoride positron emission tomography (<sup>18</sup>F-NaF PET).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were no significant differences in the 96-week changes in AVCV between evogliptin 5 mg and placebo (-5.27; 95% CI: -55.36 to 44.82; P = 0.84) or evogliptin 10 mg and placebo (-18.83; 95% CI: -32.43 to 70.10; P = 0.47). In the placebo group, the increase in AVCV between 48 weeks and 96 weeks was higher than that between baseline and 48 weeks (136 mm<sup>3</sup>; 95% CI: 108-163 vs 102 mm<sup>3</sup>; 95% CI: 75-129; P = 0.0485). This increasing trend in the second half of the study was suppressed in both evogliptin groups. The 48-week change in active calcification volume on <sup>18</sup>F-NaF PET was significantly lower in both the evogliptin 5 mg (-1,325.6; 95% CI: -2,285.9 to -365.4; P = 0.008) and 10-mg groups (-1,582.2; 95% CI: -2,610.8 to -553.5; P = 0.0038) compared with the placebo group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This exploratory study did not demonstrate the protective effect of evogliptin on AV calcification. Favorable <sup>18</sup>F-NaF PET results and possible suppression of aortic valve calcification with longer medication use in the evogliptin groups suggest the need for larger confirmatory trials. (A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease; NCT04055883).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260927</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.037>10.1016/j.jacc.2024.06.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260927</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jae-Kwan Song</dc:creator>
<dc:creator>Sahmin Lee</dc:creator>
<dc:creator>Yong-Jin Kim</dc:creator>
<dc:creator>Hyung-Kwan Kim</dc:creator>
<dc:creator>Jong-Won Ha</dc:creator>
<dc:creator>Eui-Young Choi</dc:creator>
<dc:creator>Seung-Woo Park</dc:creator>
<dc:creator>Sung-Ji Park</dc:creator>
<dc:creator>Yong-Hyun Park</dc:creator>
<dc:creator>Jae-Hyeong Park</dc:creator>
<dc:creator>Dong Heon Yang</dc:creator>
<dc:creator>Kye Hun Kim</dc:creator>
<dc:creator>Dong Hyun Yang</dc:creator>
<dc:creator>Sangwon Han</dc:creator>
<dc:creator>Sun Young Chae</dc:creator>
<dc:creator>Ji Sung Lee</dc:creator>
<dc:creator>Jong-Min Song</dc:creator>
<dc:creator>Goo-Yeong Cho</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Evogliptin on the Progression of Aortic Valvular Calcification</dc:title>
<dc:identifier>pmid:39260927</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.037</dc:identifier>
</item>
<item>
<title>Metabolic Surgery Saves Lives: Let Us Treat Obesity to Reduce the Perils of Obstructive Sleep Apnea</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260926/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1061-1063. doi: 10.1016/j.jacc.2024.07.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260926/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260926</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.012>10.1016/j.jacc.2024.07.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260926</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Francesco Gentile</dc:creator>
<dc:creator>Alberto Giannoni</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Metabolic Surgery Saves Lives: Let Us Treat Obesity to Reduce the Perils of Obstructive Sleep Apnea</dc:title>
<dc:identifier>pmid:39260926</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.012</dc:identifier>
</item>
<item>
<title>Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>Genetic medicines show promise for treating various diseases, yet clinical success has been limited by tolerability, scalability, and immunogenicity issues of current delivery platforms. To overcome these, we developed a proteolipid vehicle (PLV) by combining features from viral and non-viral approaches. PLVs incorporate fusion-associated small transmembrane (FAST) proteins isolated from fusogenic orthoreoviruses into a well-tolerated lipid formulation, using scalable microfluidic mixing....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 7:S0092-8674(24)00783-9. doi: 10.1016/j.cell.2024.07.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Genetic medicines show promise for treating various diseases, yet clinical success has been limited by tolerability, scalability, and immunogenicity issues of current delivery platforms. To overcome these, we developed a proteolipid vehicle (PLV) by combining features from viral and non-viral approaches. PLVs incorporate fusion-associated small transmembrane (FAST) proteins isolated from fusogenic orthoreoviruses into a well-tolerated lipid formulation, using scalable microfluidic mixing. Screening a FAST protein library, we identified a chimeric FAST protein with enhanced membrane fusion activity that improved gene expression from an optimized lipid formulation. Systemically administered FAST-PLVs showed broad biodistribution and effective mRNA and DNA delivery in mouse and non-human primate models. FAST-PLVs show low immunogenicity and maintain activity upon repeat dosing. Systemic administration of follistatin DNA gene therapy with FAST-PLVs raised circulating follistatin levels and significantly increased muscle mass and grip strength. These results demonstrate the promising potential of FAST-PLVs for redosable gene therapies and genetic medicines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260374</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.023>10.1016/j.cell.2024.07.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260374</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Douglas W Brown</dc:creator>
<dc:creator>Ping Wee</dc:creator>
<dc:creator>Prakash Bhandari</dc:creator>
<dc:creator>Amirali Bukhari</dc:creator>
<dc:creator>Liliya Grin</dc:creator>
<dc:creator>Hector Vega</dc:creator>
<dc:creator>Maryam Hejazi</dc:creator>
<dc:creator>Deborah Sosnowski</dc:creator>
<dc:creator>Jailal Ablack</dc:creator>
<dc:creator>Eileen K Clancy</dc:creator>
<dc:creator>Desmond Pink</dc:creator>
<dc:creator>Jitendra Kumar</dc:creator>
<dc:creator>Maria Paola Solis Ares</dc:creator>
<dc:creator>Suellen Lamb</dc:creator>
<dc:creator>Rodrigo Quevedo</dc:creator>
<dc:creator>Bijal Rawal</dc:creator>
<dc:creator>Fahed Elian</dc:creator>
<dc:creator>Natasha Rana</dc:creator>
<dc:creator>Luis Morales</dc:creator>
<dc:creator>Natasha Govindasamy</dc:creator>
<dc:creator>Brendan Todd</dc:creator>
<dc:creator>Angela Delmage</dc:creator>
<dc:creator>Somnath Gupta</dc:creator>
<dc:creator>Nichole McMullen</dc:creator>
<dc:creator>Duncan MacKenzie</dc:creator>
<dc:creator>Perrin H Beatty</dc:creator>
<dc:creator>Henry Garcia</dc:creator>
<dc:creator>Manoj Parmar</dc:creator>
<dc:creator>Jennifer Gyoba</dc:creator>
<dc:creator>Chandra McAllister</dc:creator>
<dc:creator>Matthew Scholz</dc:creator>
<dc:creator>Roy Duncan</dc:creator>
<dc:creator>Arun Raturi</dc:creator>
<dc:creator>John D Lewis</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles</dc:title>
<dc:identifier>pmid:39260374</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.023</dc:identifier>
</item>
<item>
<title>Biomolecular condensates regulate cellular electrochemical equilibria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>Control of the electrochemical environment in living cells is typically attributed to ion channels. Here, we show that the formation of biomolecular condensates can modulate the electrochemical environment in bacterial cells, which affects cellular processes globally. Condensate formation generates an electric potential gradient, which directly affects the electrochemical properties of a cell, including cytoplasmic pH and membrane potential. Condensate formation also amplifies cell-cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 6:S0092-8674(24)00909-7. doi: 10.1016/j.cell.2024.08.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Control of the electrochemical environment in living cells is typically attributed to ion channels. Here, we show that the formation of biomolecular condensates can modulate the electrochemical environment in bacterial cells, which affects cellular processes globally. Condensate formation generates an electric potential gradient, which directly affects the electrochemical properties of a cell, including cytoplasmic pH and membrane potential. Condensate formation also amplifies cell-cell variability of their electrochemical properties due to passive environmental effect. The modulation of the electrochemical equilibria further controls cell-environment interactions, thus directly influencing bacterial survival under antibiotic stress. The condensate-mediated shift in intracellular electrochemical equilibria drives a change of the global gene expression profile. Our work reveals the biochemical functions of condensates, which extend beyond the functions of biomolecules driving and participating in condensate formation, and uncovers a role of condensates in regulating global cellular physiology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39260373</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.018>10.1016/j.cell.2024.08.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260373</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yifan Dai</dc:creator>
<dc:creator>Zhengqing Zhou</dc:creator>
<dc:creator>Wen Yu</dc:creator>
<dc:creator>Yuefeng Ma</dc:creator>
<dc:creator>Kyeri Kim</dc:creator>
<dc:creator>Nelson Rivera</dc:creator>
<dc:creator>Javid Mohammed</dc:creator>
<dc:creator>Erica Lantelme</dc:creator>
<dc:creator>Heileen Hsu-Kim</dc:creator>
<dc:creator>Ashutosh Chilkoti</dc:creator>
<dc:creator>Lingchong You</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Biomolecular condensates regulate cellular electrochemical equilibria</dc:title>
<dc:identifier>pmid:39260373</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.018</dc:identifier>
</item>
<item>
<title>Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259546/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the SAHELI randomized clinical trial, a culturally adapted, group lifestyle intervention was not more effective than written health education materials for CVD risk factor reduction among US South Asian adults, but the intervention was associated with small improvements in self-reported health behaviors. Effective CVD prevention interventions for this elevated-risk population require further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 11. doi: 10.1001/jamacardio.2024.2526. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: South Asian adults in the US experience excess cardiovascular disease (CVD) compared with other racial and ethnic groups. The effectiveness and reach of guideline-recommended lifestyle interventions have not been evaluated in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate whether a culturally adapted, group lifestyle intervention will improve CVD risk factors more effectively than written health education materials among US South Asian adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This single-blind randomized clinical trial was conducted from March 6, 2018, to February 11, 2023 at community sites in the Chicago, Illinois, metropolitan area. South Asian adults aged 18 to 65 years who were overweight or obese, had no history of CVD events, and had at least 1 additional CVD risk factor (hypertension, dyslipidemia, prediabetes, or diabetes) were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: A 16-week, culturally adapted, group-based lifestyle intervention led by community health coaches. Lifestyle modification counseling was delivered in English, Gujarati, Hindi, and Urdu. Participants tracked their diet and physical activity (PA) and received 4 optional group maintenance sessions between months 5 and 11 of follow-up. The intervention was delivered in person prior to the onset of the COVID-19 pandemic and via videoconference starting in March 2020. The control group received written health education materials, delivered monthly.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary outcomes were the between-group differences in CVD risk factor changes from baseline to 12 months, including weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), glycated hemoglobin (HbA1c), and total cholesterol, estimated using multivariate mixed-effects regression models. Secondary outcomes were self-reported diet quality, PA, and self-efficacy, estimated using univariate mixed-effects regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 549 randomized participants, 318 (57.9%) were women, and mean (SD) participant age was 49.2 (9.5) years. Mean differences in CVD risk factor changes from baseline to 12 months in the intervention vs control group were calculated for weight (mean difference, -0.07 kg; 95% CI, -0.55 to 0.42), SBP (mean difference, 0.47 mm Hg; 95% CI, -1.85 to 2.79), DBP (mean difference, 0.44 mm Hg; 95% CI, -1.06 to 1.95), cholesterol (mean difference, -2.47 mg/dL; 95% CI, -8.51 to 3.57), and HbA1c (mean difference, -0.07%; 95% CI -0.20% to 0.07%). Intervention participation was associated with greater improvements in dietary quality, PA, and self-efficacy than control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the SAHELI randomized clinical trial, a culturally adapted, group lifestyle intervention was not more effective than written health education materials for CVD risk factor reduction among US South Asian adults, but the intervention was associated with small improvements in self-reported health behaviors. Effective CVD prevention interventions for this elevated-risk population require further investigation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03336255.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259546/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259546</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2526>10.1001/jamacardio.2024.2526</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259546</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Namratha R Kandula</dc:creator>
<dc:creator>Nirav S Shah</dc:creator>
<dc:creator>Santosh Kumar</dc:creator>
<dc:creator>Michael Charley</dc:creator>
<dc:creator>Margaret Clauson</dc:creator>
<dc:creator>Nicola Lancki</dc:creator>
<dc:creator>Emily A Finch</dc:creator>
<dc:creator>Linda Ehrlich-Jones</dc:creator>
<dc:creator>Goutham Rao</dc:creator>
<dc:creator>Bonnie Spring</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Juned Siddique</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39259546</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2526</dc:identifier>
</item>
<item>
<title>On the Road to Disclose the Pathogenesis of Pericarditis-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 11. doi: 10.1001/jamacardio.2024.2795. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259532</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2795>10.1001/jamacardio.2024.2795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259532</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rosa B Thorolfsdottir</dc:creator>
<dc:creator>Daniel F Gudbjartsson</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>On the Road to Disclose the Pathogenesis of Pericarditis-Reply</dc:title>
<dc:identifier>pmid:39259532</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2795</dc:identifier>
</item>
<item>
<title>On the Road to Disclose the Pathogenesis of Pericarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 11. doi: 10.1001/jamacardio.2024.2792. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259528</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2792>10.1001/jamacardio.2024.2792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259528</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Antonio Brucato</dc:creator>
<dc:creator>Humaid Almualla</dc:creator>
<dc:creator>Massimo Imazio</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>On the Road to Disclose the Pathogenesis of Pericarditis</dc:title>
<dc:identifier>pmid:39259528</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2792</dc:identifier>
</item>
<item>
<title>Errors in Percentage Values</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259522/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 11. doi: 10.1001/jamacardio.2024.3111. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259522/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259522</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3111>10.1001/jamacardio.2024.3111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259522</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Errors in Percentage Values</dc:title>
<dc:identifier>pmid:39259522</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3111</dc:identifier>
</item>
<item>
<title>Addressing Lifestyle Patterns Among South Asian Individuals in the US: Implementing Meaningful Clinical Change Remains a Challenge</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 11. doi: 10.1001/jamacardio.2024.2832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259520</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2832>10.1001/jamacardio.2024.2832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259520</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Anand Rohatgi</dc:creator>
<dc:creator>Parul Sharma</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Addressing Lifestyle Patterns Among South Asian Individuals in the US: Implementing Meaningful Clinical Change Remains a Challenge</dc:title>
<dc:identifier>pmid:39259520</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2832</dc:identifier>
</item>
<item>
<title>Error in Abstract</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 1;9(9):861. doi: 10.1001/jamacardio.2024.3130.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259261</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3130>10.1001/jamacardio.2024.3130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259261</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Abstract</dc:title>
<dc:identifier>pmid:39259261</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3130</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39259260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 1;9(9):764. doi: 10.1001/jamacardio.2023.3675.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39259260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39259260</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3675>10.1001/jamacardio.2023.3675</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39259260</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39259260</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3675</dc:identifier>
</item>
<item>
<title>Red blood cells: a new target to prevent cardiovascular disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39258963/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 11:ehae454. doi: 10.1093/eurheartj/ehae454. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39258963/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39258963</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae454>10.1093/eurheartj/ehae454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39258963</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John Pernow</dc:creator>
<dc:creator>Jiangning Yang</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Red blood cells: a new target to prevent cardiovascular disease?</dc:title>
<dc:identifier>pmid:39258963</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae454</dc:identifier>
</item>
<item>
<title>The multifaceted impact of warfare on cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39258907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 11:ehae437. doi: 10.1093/eurheartj/ehae437. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39258907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39258907</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae437>10.1093/eurheartj/ehae437</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39258907</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rasha Kaddoura</dc:creator>
<dc:creator>Mohammed Al-Hijji</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The multifaceted impact of warfare on cardiovascular health</dc:title>
<dc:identifier>pmid:39258907</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae437</dc:identifier>
</item>
<item>
<title>Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the ADMIRE Pivotal Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39258362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240912061131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ADMIRE confirmed the safety and effectiveness of the variable-loop PFA catheter, with short procedure and PFA application times and low fluoroscopy exposure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 11. doi: 10.1161/CIRCULATIONAHA.124.070333. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Evidence from clinical trials of early pulsed field ablation (PFA) systems in treating atrial fibrillation has demonstrated their promising potential to reduce complications associated with conventional thermal modalities while maintaining efficacy. However, the lack of a fully integrated mapping system, a staple technology of most modern electrophysiology procedures, poses limitations in lesion creation and workflow options. A novel variable-loop PFA catheter integrated with an electroanatomic mapping system has been developed that allows for real-time nonfluoroscopic procedural guidance and lesion indexing as well as feedback of tissue-to-catheter proximity. ADMIRE (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bosense-Webster Irreversible Electroporation Ablation System), a multicenter, single-arm, Food and Drug Administration investigational device exemption study, evaluated the long-term safety and effectiveness of this integrated PFA system in a large United States-based drug-refractory symptomatic paroxysmal atrial fibrillation patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the PFA catheter with a compatible electroanatomic mapping system, patients with drug-refractory symptomatic paroxysmal atrial fibrillation underwent pulmonary vein isolation. The primary safety end point was primary adverse event within 7 days of ablation. The primary effectiveness end point was a composite end point that included 12-month freedom from documented atrial tachyarrhythmia (ie, atrial fibrillation, atrial tachycardia, atrial flutter) episodes, failure to achieve pulmonary vein isolation, use of a nonstudy catheter for pulmonary vein isolation, repeat procedure (except for one redo during blanking), taking a new or previously failed class I or III antiarrhythmic drug at higher dose after blanking, or direct current cardioversion after blanking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 30 centers, 277 patients with paroxysmal atrial fibrillation (61.5±10.3 years of age; 64.3% male) in the pivotal cohort underwent PFA. More than 25% of the procedures were performed without fluoroscopy. Median (Q1, Q3) pulmonary vein isolation procedure, fluoroscopy, and transpired PFA application times were 81.0 (61.0, 112.0), 7.1 (0.00, 14.3), and 31.0 (24.8, 40.9) minutes, respectively. The primary adverse event rate was 2.9% (8 of 272), with the most common complication being pericardial tamponade. The 12-month primary effectiveness end point was 74.6%. The 1-year freedom from atrial fibrillation, atrial tachycardia, or atrial flutter recurrence rate after blanking was 75.4%. Substantial improvements in quality of life were observed as early as 3 months after the procedure, concurrent with a reduction in multiple health care use measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ADMIRE confirmed the safety and effectiveness of the variable-loop PFA catheter, with short procedure and PFA application times and low fluoroscopy exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05293639.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39258362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240912061131&v=2.18.0.post9+e462414">39258362</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070333>10.1161/CIRCULATIONAHA.124.070333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39258362</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Moussa Mansour</dc:creator>
<dc:creator>Oussama Wazni</dc:creator>
<dc:creator>Luigi Di Biase</dc:creator>
<dc:creator>Marwan Bahu</dc:creator>
<dc:creator>David Newton</dc:creator>
<dc:creator>Christopher F Liu</dc:creator>
<dc:creator>William H Sauer</dc:creator>
<dc:creator>Sandeep Goyal</dc:creator>
<dc:creator>Vivek Iyer</dc:creator>
<dc:creator>Devi Nair</dc:creator>
<dc:creator>Charles Athill</dc:creator>
<dc:creator>Ayman Hussein</dc:creator>
<dc:creator>Patrick Whalen</dc:creator>
<dc:creator>Daniel Melby</dc:creator>
<dc:creator>Andrea Natale</dc:creator>
<dc:creator>ADMIRE trial investigators</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the ADMIRE Pivotal Trial</dc:title>
<dc:identifier>pmid:39258362</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070333</dc:identifier>
</item>





























</channel>
</rss>